Novo Nordisk to pay up to $2.6B to China's Hengrui for once-weekly oral GLP-1/GIP obesity drug
The licensing deal adds a preclinical once-weekly oral GLP-1/GIP dual agonist, HRS-1596, to Novo's pipeline as competition in oral obesity treatments intensifie
BioPharma Dive · +13 outlets
Trump signs executive order imposing 100% tariff on some branded pharmaceutical imports
The order applies tariffs to patented and branded drugmakers while detailing exemptions for select specialty drugs and ingredients, with India and other supplie
Managed Healthcare Executive · +13 outlets
Most powerful obesity drug yet: trial participants lost up to 25% of body weight
Data presented at a Milan conference show a next-generation obesity candidate surpassing the weight loss seen with the active ingredient in Zepbound.
Ars Technica · +14 outlets
India's Supreme Court flags 10-fold cancer drug markups, seeks uniform 16% retail margin cap
The court's call for a standardized markup aims to curb wide pricing disparities on medicines including cancer drugs.
Telangana Today · +7 outlets
uniQure shares crash as 48-month Huntington's gene therapy data disappoint investors
Mixed longer-term results for AMT-130 prompted a sharp selloff and also dragged down partner ClearPoint Neuro's stock.
Fierce Biotech · +13 outlets
Kodiak Sciences stock soars after two eye disease assets match Eylea in Phase 3 trial
Positive Phase 3 results for the retinal disease candidates lifted shares sharply, reviving the company's outlook.
BioSpace · +4 outlets
FDA clears Immunome IND for cancer drug IM-1340, first study expected in Q4 2026
The clearance allows Immunome to begin human testing of an antibody-drug candidate targeting cancer.
Stock Titan · +4 outlets
DBV Technologies files FDA application for VIASKIN peanut allergy patch in children aged 4-7
The BLA submission moves the patch closer to a potential first-in-class approval for peanut allergy immunotherapy in young children.
Ideal Investisseur · +9 outlets
Roche drops muscle-sparing obesity drug after mid-stage disappointment, returns it to Chugai
The setback removes one candidate from the race to develop obesity therapies that preserve lean muscle mass.
BioSpace · +2 outlets
Citi downgrades Moderna, calls valuation stretched despite cancer vaccine momentum
The analyst note weighed on the stock premarket as investors reassessed the company's pipeline prospects.
TradingView · +5 outlets
Eli Lilly to build $3.5 billion Pennsylvania manufacturing plant for weight-loss drugs
The investment expands US production capacity for GLP-1 obesity medicines amid surging demand.
polskieradio.pl · +14 outlets
Eli Lilly's Olumiant wins FDA approval for expanded use in adolescent alopecia areata
The approval extends the JAK inhibitor's label to adolescents with severe hair loss.
TradingView · +7 outlets
FDA approves Pfizer's Ibrance for HR-positive, HER2-positive metastatic breast cancer
The label expansion broadens use of the CDK4/6 inhibitor to a new breast cancer subtype.
scanx.trade · +14 outlets
Invivyd COVID-19 antibody trial shows fewer adverse events than mRNA vaccine, stock falls
In a 210-patient study, event rates differed notably between the antibody and vaccine arms even as shares declined.
Stock Titan · +4 outlets
US guidance details 0% specialty pharmaceutical tariff exemptions
The exemption rules clarify which specialty drugs and ingredients avoid the new 100% tariffs.
Fierce Pharma · +5 outlets
Trump holds Oval Office announcement on weight loss drug costs
The event follows a second wave of drug pricing deals and continued pressure on GLP-1 pricing.
polskieradio.pl · +12 outlets
Grail stock up 180% in six months as analysts see more upside after PATHFINDER 2 data
Coverage points to continued momentum for the multi-cancer early detection company after trial results and an FDA panel vote.
AOL.com · +1 outlets
Connect Biopharma reports preliminary data with fewer treatment failures but a missed lung-function target
Mixed early results left the company's lung disease program facing questions about its primary endpoint.
Stock Titan · +1 outlets